Roth Capital Issues Optimistic Estimate for Enovis Earnings

Enovis Co. (NYSE:ENOV) – Analysts at Roth Capital increased their FY2025 earnings per share estimates for shares of Enovis in a report released on Wednesday, November 6th. Roth Capital analyst J. Wittes now anticipates that the company will earn $3.31 per share for the year, up from their previous estimate of $3.03. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis’ FY2026 earnings at $3.99 EPS.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.62 by $0.11. The business had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company’s quarterly revenue was up 21.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.56 EPS.

Several other equities research analysts have also weighed in on ENOV. JPMorgan Chase & Co. dropped their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Evercore ISI cut their price objective on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st. Needham & Company LLC restated a “buy” rating and issued a $65.00 target price on shares of Enovis in a research report on Thursday, November 7th. Finally, JMP Securities started coverage on Enovis in a report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price target on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $67.00.

Enovis Stock Down 0.9 %

Shares of Enovis stock opened at $46.91 on Monday. The stock has a market capitalization of $2.62 billion, a price-to-earnings ratio of -21.42 and a beta of 1.91. Enovis has a twelve month low of $38.27 and a twelve month high of $65.03. The company has a current ratio of 2.27, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. The business’s 50 day simple moving average is $42.29 and its 200-day simple moving average is $45.32.

Institutional Investors Weigh In On Enovis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC raised its stake in shares of Enovis by 18.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 4,879 shares of the company’s stock worth $305,000 after buying an additional 765 shares in the last quarter. Texas Permanent School Fund Corp lifted its holdings in Enovis by 2.2% in the 1st quarter. Texas Permanent School Fund Corp now owns 43,480 shares of the company’s stock valued at $2,715,000 after acquiring an additional 932 shares during the last quarter. Duality Advisers LP boosted its position in shares of Enovis by 76.5% during the 1st quarter. Duality Advisers LP now owns 9,336 shares of the company’s stock valued at $583,000 after purchasing an additional 4,045 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in shares of Enovis by 21.0% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 6,272 shares of the company’s stock worth $392,000 after purchasing an additional 1,087 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of Enovis by 0.3% in the 1st quarter. Swiss National Bank now owns 97,000 shares of the company’s stock worth $6,058,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.